Abyss Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 27 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.08 M
- Revenue Growth 10.49%
- Profit Growth -55.21%
- Ebitda 27.51%
- Net Worth 27.13%
- Total Assets -3.71%
About Abyss Pharma
Abyss Pharma Private Limited (APPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 03 June 1997 and has a history of 27 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.08 M.
Nitin Gupta and Vimal Gupta serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24232DL1997PTC087663
-
Company No.
087663
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Jun 1997
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Abyss Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nitin Gupta
|
Director | 30-Nov-2022 | Current |
|
Vimal Gupta
|
Director | 03-Jun-1997 | Current |
Financial Performance of Abyss Pharma.
Abyss Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.49% increase. The company also saw a substantial fall in profitability, with a 55.21% decrease in profit. The company's net worth Soared by an impressive increase of 27.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abyss Pharma?
Unlock access to Abyss Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Explores Hr Services LlpVimal Gupta is a mutual person
Charges (Loans)
₹5.08 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.36 Cr
- Hdfc Bank Limited : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Nov 2023 | Hdfc Bank Limited | ₹1.50 M | Open |
| 16 Nov 2021 | Others | ₹3.58 M | Open |
How Many Employees Work at Abyss Pharma?
Abyss Pharma has a workforce of 17 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abyss Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abyss Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
